Val279Phe variant of Lp-PLA2 is a risk factor for a subpopulation of Indonesia patients with acute myocardial infarction

• Published in: Genes & diseases Vol. 3; no. 4; pp. 289 - 293
• Main Authors: Cahyaningtias, Miryanti, Rohman, Mohammad Saifur, Widodo, Wahjono Adi, Andi, Yuda, Rina, Indrayana, Yanna, Putri, Jayarani Fatimah, Rusdianto, Lukitasari, Mifetika, Hendrawan, Dadang
• Format: Journal Article
• Language: English
• Published: China Elsevier B.V 01.12.2016; Chongqing Medical University; KeAi Communications Co., Ltd
• Subjects: Acute myocardial infarction; AMI predictor; Atherosclerosis; Lp-PLA2; Val279Phe; Acute myocardial infarction; AMI predictor; Lp-PLA2; Val279Phe; Atherosclerosis
• ISSN: 2352-3042; 2352-4820; 2352-3042
• DOI: 10.1016/j.gendis.2016.08.002

Lipoprotein-associated phospholipase A2 (Lp-PLA2), a member of the phospholipase A2 superfamily, is an enzyme that hydrolyses phospholipids, is found in blood circulation as a sign of inflammation, and takes a role in atherogenesis. There is an epidemiologic relation between increased Lp-PLA2 levels and coronary heart disease. Lp-PLA2 is an enzyme that is produced by macrophages and takes a role as an independent predictor of a coronary event. A genetic variant of Val279Phe on the Lp-PLA2 gene has been reported with various results in Japan, China, Korea, and Caucasian populations. This study aims to analyse the influence of the Val279Phe genetic variant on acute myocardial infarction (AMI) at Saiful Anwar Hospital, Indonesia. This study was conducted on 151 patients (111 AMI patients and 40 non-AMI patients). The genetic variant of Val279Phe was identified through a genotyping method. There were no significant differences in age, total cholesterol level, LDL-C (low-density lipoprotein cholesterol) level, and family history data between AMI and non-AMI patients. However, AMI patients had low HDL-C (high-density lipoprotein cholesterol), triglyceride levels, dyslipidaemia, and hypertension risk factors compared to non-AMI patients. The frequency of the GG genotype (279Val) was dominant in both AMI and non-AMI groups. Further analysis suggested that the GG genotype has a 2.9 times greater risk of AMI compared to the GT/TT genotype (279Phe). This study concluded that the Val279Phe genetic variant undoubtedly influenced AMI risk, which is a warrant for further development of early detection and improving strategy to prevent AMI in patients.